← Back to Search
Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)
Houston, TX
N/A
Waitlist Available
Led By Nancy D. Perrier, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights
No Placebo-Only Group
Summary
OBJECTIVES: The primary objective of this study is to evaluate the effect of estrogen on the development of the PNET in MEN1 patients. The secondary objective is to evaluate the overall survival and disease specific survival in patients who have confirmed MEN1 with or without PNET and a pancreatic neuroendocrine tumor in relation to their hormone status. The secondary objective is to evaluate clinicopathologic features in relation to hormone status.
Eligible Conditions
- Multiple endocrine neoplasia
- Mutations
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Time to Pancreatic Neuroendocrine Tumors (PNET)
Secondary study objectives
Overall Survival in Participants Who Have Confirmed MEN1 with or without PNET
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Participants With Confirmed MEN1 Without PNETExperimental Treatment2 Interventions
Retrospective review of a prospectively maintained MEN1 database.
Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
Group II: Participants With Confirmed MEN1 With PNETExperimental Treatment2 Interventions
Retrospective review of a prospectively maintained MEN1 database.
Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Questionnaire
2014
Completed Phase 2
~19970
Find a Location
Closest Location:University of Texas MD Anderson Cancer Center· Houston, TX
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,105 Previous Clinical Trials
1,813,022 Total Patients Enrolled
Nancy D. Perrier, MDPrincipal InvestigatorM.D. Anderson Cancer Center
10 Previous Clinical Trials
27,591 Total Patients Enrolled